India Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the country now has a narrow window to build the clinical-development capabilities needed to originate and test novel therapies itself. India…
APAC The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather than incremental process tweaks. That growth is already visible on the ground in APAC: AI has moved well beyond the…
Korea Korea’s position as a clinical trials hub did not happen overnight. The country has treated clinical development as a matter of deliberate government policy for the better part of two decades, with Korea ranking among the world’s leading trial destinations as far back as 2018; years before China’s biotech ambitions…
Japan Japan is resetting itself as a clinical trial destination. Costs have halved, local data requirements are being relaxed, and the country is actively courting the global biotechs that have long overlooked it for trials. The opportunity is real; but so is the ground Japan still must make up. Japan’s…
Taiwan Taiwan’s population of just 23 million people and contested political status should, in theory, harm its chances of becoming a globally relevant clinical trials hub. In fact, these two factors – which have forced the island to adopt the most rigorous international standards and build a dense web of global…
China China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the global drug development pipeline. The high speed and low cost of Chinese trials are unmatched globally. However, in a volatile…
Singapore Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and Project Orbis. Writing in the September 2026 edition of DIA Global Forum, Sandy Chan, Sok Bee Lim, Shirley Yong, and…
Japan We have evolved well beyond the traditional CRO model Global biopharma companies are looking at Japan through a different lens, seeking partners that can navigate an increasingly complex regulatory landscape while supporting integrated development across Asia. At the heart of that evolution is CMIC, whose President and Representative Executive Officer,…
APAC For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is no longer the one APAC’s own CRO leaders make. Asia Pacific is now the only region in the world where…
Japan Hideyasu Matsuda and Toru Fujieda of the Japan CRO Association argue that, thanks to an updated regulatory framework, Japan is becoming one of the most competitive and operationally attractive clinical development destinations in the world. Japan is an attractive clinical trial destination from a cost, quality, and speed perspective…
Korea Kwunho Jeong, CEO of JNPMEDI, is building an integrated clinical development platform that combines proprietary software, CRO services, and biotech investment to strengthen Asia’s drug development ecosystem. A former consultant and fintech executive, he views clinical trials as fundamentally a data management challenge. Through AI, blockchain-based data integrity, and strategic…
APAC Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s shift into a global clinical development hub, the rise of Greater China as a leading source of innovation, with mainland…
See our Cookie Privacy Policy Here
